cas 3034-22-8|| where to buy 5-bromo-1,3-thiazol-2-amine

Nom du produit:5-bromo-1,3-thiazol-2-amine

IUPAC Name:5-bromo-1,3-thiazol-2-amine

Unité d'emballage	Stock disponible	Prix($)
CM104786-25g	in stock	Ƥǆ
CM104786-100g	in stock	ſƋƋ
CM104786-500g	in stock	Ƽȱɐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Notes supplémentaires

Verification code*

refresh

: N° CAS:3034-22-8; Formule moléculaire:C3H3BrN2S; Point de fusion:-; Code SMILES:NC1=NC=C(Br)S1; Densité:

: Numéro de catalogue:CM104786; Poids moléculaire:179.04; Point d'ébullition:; N° Mdl:MFCD00016893; Stockage:

: Thiazoles; Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.

: Cadisegliatin; vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.